This study is about testing a new drug called telisotuzumab adizutecan for treating a type of cancer that has spread, known as metastatic colorectal cancer (mCRC). The study combines this new drug with other drugs like oxaliplatin, fluorouracil (5FU), leucovorin (LV), and bevacizumab or panitumumab. The study has two parts: first, they will try different doses to find the best one that works without causing too many side effects. Then, they will compare this dose with standard treatments. About 390 adults will participate, and it will take place in 100 places worldwide over about 6 years. Participants need to visit the hospital or clinic regularly for check-ups and tests to see how the treatment is working.

• The study lasts for around 6 years with regular hospital visits.
• Participants may experience more side effects than usual care.
• Frequent medical checks are necessary to monitor treatment effects.